ADC Therapeutics ADCT Cash Flow Statement (2020-2026)

NYSE ADCT
$1.22 -0.08 (-6.15%)
As of: Sep 9, 2026 · 3:59 PM EDT
Reported Financials

ADC Therapeutics Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

ADC Therapeutics reported cash from operations of -$11.81M and free cash flow of -$11.81M for the quarter ended Jun 2026, up 51.0% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-71.55M-16.66M-64.37M-50.61M-59.43M-48.20M-45.30M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M-16.57M
Share-based CompensationStock Comp.
14.80M13.46M13.40M13.82M14.56M7.54M8.07M1.12M2.08M2.22M0.16M1.99M2.81M1.62M2.42M1.81M2.00M0.67M2.44M4.55M
Deferred Taxes
-0.07M-5.10M-0.58M42.85M
Gains from Investment SecuritiesGains Investment
-0.62M-0.02M-0.14M0.28M3.07M2.23M-1.13M-0.00M-2.23M-14.40M
Asset Writedowns and ImpairmentWritedown
0.05M0.73M0.83M0.75M0.29M0.48M1.25M0.39M0.24M0.41M1.47M0.17M
Cash from OperationsCash from Ops.
-58.59M-61.63M-33.88M-53.01M2.19M-53.61M-15.39M-34.99M-36.67M-31.63M-44.09M-32.84M-25.04M-21.85M-56.33M-24.09M-29.63M-31.12M-29.71M-11.81M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.46M0.54M0.57M0.51M0.51M0.51M0.47M0.45M0.46M0.48M0.12M0.11M0.11M
Amortization of Deferred ChargesAmort. Deferred Charges
0.50M0.44M0.52M-0.56M0.19M0.65M0.73M0.25M0.23M0.94M
Change in Working Capital
Change in ReceivablesChange Receivables
-13.82M-14.32M3.47M5.89M-2.42M35.82M-48.90M-0.19M-2.70M4.00M-2.00M-0.32M1.26M-3.71M11.45M-5.58M-3.27M6.19M1.93M-3.01M
Change in InventoryChange Inventory
0.35M2.05M3.48M-0.17M0.57M-0.52M0.88M2.80M0.31M0.71M0.52M0.85M-0.02M3.29M
Change in Account PayablesChange Payables
-3.93M1.74M4.38M-3.41M-1.38M0.72M-3.66M2.98M-2.71M6.57M-1.25M-4.84M4.87M3.68M-2.46M-6.22M-1.29M0.93M-3.87M7.47M
Change in Accured ExpensesChange Accured Exp.
-12.30M-3.29M-0.52M1.96M-3.54M-2.19M5.57M11.30M-20.63M12.04M-0.80M1.97M-3.18M3.82M
Change in TaxesChange Taxes
0.06M0.08M
Other Working Capital ChangesOther WC Changes
-0.64M-4.29M-1.31M-1.04M0.42M0.44M1.20M-0.57M
Investing Activities
Capital ExpendituresCapex
1.41M0.42M0.23M0.05M0.19M0.21M1.02M1.21M0.66M0.33M0.53M0.03M0.22M0.09M0.26M0.03M
Cash from Investing ActivitiesCash from Investing
-2.34M-0.83M-1.45M-0.69M-0.25M1.70M-1.02M-1.21M-0.66M-0.33M-0.53M-0.03M-0.22M-0.09M-0.26M0.66M-0.03M
Financing Activities
Other financing activitiesOther financing
0.42M0.35M-0.00M0.32M36.60M0.27M50.49M14.61M0.20M0.12M
Cash from Financing ActivitiesCash from Financing
219.30M-1.22M-0.26M-0.25M2.37M-2.75M0.42M73.10M0.35M-0.00M0.36M98.70M-0.88M-1.12M0.27M93.78M-0.20M57.09M-0.58M-0.10M
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued
-1.23M43.24M43.52M-0.02M
Additional items
Exchange Rate EffectFX Effect
-0.07M0.03M-0.08M-0.14M-0.22M0.24M0.09M0.06M-0.12M0.15M-0.04M0.01M0.29M-0.34M0.16M0.16M0.01M-0.03M-0.01M0.01M
Change in Cash
-15.98M36.90M-36.98M-31.96M-44.27M65.82M-26.14M-23.06M-56.33M69.70M-29.83M26.62M-30.32M-11.91M
Free Cash FlowFCF
-59.99M-62.05M-34.11M-53.06M2.00M-53.83M-16.41M-36.20M-37.33M-31.96M-44.63M-32.88M-25.26M-21.94M-56.60M-24.09M-29.63M-31.12M-29.74M-11.81M
Net Cash FlowNCF
158.38M-63.68M-35.59M-53.95M4.31M-54.66M-15.98M36.90M-36.98M-31.96M-44.27M65.82M-26.14M-23.06M-56.33M69.70M-29.83M26.62M-30.32M-11.91M